Get the Stockscreener App
2.65
0.38%
-0.01
Sonoma Pharmaceuticals Inc stock is traded at $2.65, with a volume of 30,186.
It is down -0.38% in the last 24 hours and down -1.49% over the past month.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
See More
Previous Close:
$2.66
Open:
$2.66
24h Volume:
30,186
Relative Volume:
0.10
Market Cap:
$3.55M
Revenue:
$12.31M
Net Income/Loss:
$-5.08M
P/E Ratio:
-2.8191
EPS:
-0.94
Net Cash Flow:
$-5.20M
1W Performance:
-0.38%
1M Performance:
-1.49%
6M Performance:
-55.83%
1Y Performance:
-19.21%
1-Day Range:
$2.594
$2.6899
1-Week Range:
$2.53
$2.85
52-Week Range:
$2.44
$9.374
Sonoma Pharmaceuticals Inc Stock (SNOA) Company Profile
Name
Sonoma Pharmaceuticals Inc
Sector
Phone
800-759-9305
Address
5445 CONESTOGA COURT, SUITE 150, BOULDER, CA
Compare SNOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNOA
Sonoma Pharmaceuticals Inc
|
2.65 | 3.55M | 12.31M | -5.08M | -5.20M | -0.94 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Sonoma Pharmaceuticals Inc Stock (SNOA) Latest News
Sonoma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 - Marketscreener.com
Sonoma Pharmaceuticals (SNOA) to Release Quarterly Earnings on Thursday - Defense World
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results - ACCESS Newswire
Sonoma Pharmaceuticals secures new supply agreement - MSN
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Sonoma Pharmaceuticals secures new supply agreement By Investing.com - Investing.com South Africa
Dental Market Future Business Opportunities 2025-2032 | - openPR
Hypertrophic And Keloid Scar Treatment Global Market Expected To Ascend to $12.51 Billion By 2029 - WhaTech
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Industry Decline - GuruFocus.com
Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences - ACCESS Newswire
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany - ACCESS Newswire
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea - ACCESS Newswire
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections - ACCESS Newswire
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma County Sheriff arrests 3, seizes guns and fentanyl in drug bust - CBS San Francisco
Global Hypertrophic And Keloid Scar Treatment Market: Key - openPR
Animal Wound Care Market: Exploring Projected Size, CAGR, Key Players & Trends - openPR
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Scar Treatment Market to Surge with 10.9% CAGR, Global Revenue to Exceed US$ 8.24 Billion by 2034 - EIN News
Redhill Biopharma (NASDAQ:RDHL) Stock Quotes, Forecast and News Summary - Benzinga
Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Dental Market Set to Witness Significant Growth by 2025-2032: Sonoma Pharmaceuticals, Inc., Henry Schein, Inc, - EIN News
Scar Treatment Market Analysis: Key Drivers and Growth Projections Through 2027 - openPR
Sonoma Pharmaceuticals announces executive equity grants By Investing.com - Investing.com Australia
Sonoma Pharmaceuticals announces executive equity grants - Investing.com India
Despite Fast-paced Momentum, Sonoma Pharmaceuticals (SNOA) Is Still a Bargain Stock - MSN
Sonoma Pharmaceuticals, Inc. Announces Two Singapore Approvals for Microcyn for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars - Marketscreener.com
Urinary Catheters Market Set to Witness Significant Growth by 2024-2031 | B. Braun SE, Coloplast Corp, BD, Cathetrix - openPR
Keloid Treatment Market Top PlayersNovartis AG, Sensus - openPR
2 Sonoma County men busted for alleged drug dealing in Marin - KRON4
Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
SNOA stock touches 52-week low at $2.44 amid market challenges - Investing.com Canada
SNOA stock touches 52-week low at $2.44 amid market challenges By Investing.com - Investing.com South Africa
Bags of cocaine, gun found in Santa Rosa drug bust - KRON4
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Sonoma Pharmaceuticals (SNOA) Stock Surges Amid Market Fluctuati - GuruFocus.com
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges - Investing.com Canada
SNOA Stock Hits 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - AccessWire
Sonoma Pharmaceuticals (SNOA) Stock Declines Amid Market Activit - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) PE Ratio : At Loss (As of Nov. 30, 2024) - GuruFocus.com
SNOA (Sonoma Pharmaceuticals) Debt-to-Equity : 0.05 (As of Sep. 2024) - GuruFocus.com
Sonoma Pharmaceuticals (STU:O8Z) Growth Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Eye Care Product Lines - Trend Hunter
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - BioSpace
Sonoma Pharmaceuticals, Inc. Receives New FDA 510(K) Clearance for Microcyn(R)-Based Wound Care Hydrogel - Marketscreener.com
Scar Treatment Market Detailed In New Research Report 2024 | - openPR
Sonoma Pharmaceuticals Inc Stock (SNOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):